Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

 Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

Shots:

  • Roche has initiated the P-III program for fenebrutinib (BTK inhibitor) in RMS and PPMS which include two identical P-III trials in RMS (FENhance 1& FENhance 2) and one P-III trial in PPMS (named FENtrepid). The studies target clinical disability progression and have a 1EPs of 12wks. cCDP-12, with the addition of a co-primary endpoint of ARR in the RMS studies
  • Roche is initiating two new P-IIIb trials, one in RMS (MUSETTE) and one in PPMS (GAVOTTE), which will assess a higher OCREVUS dose vs its 600mg dose, with both evaluated at the twice-yearly (six-monthly) dosing schedule
  • Additionally, Roche has initiated P-IV CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) study in African-Americans and Hispanic- and Latinx-Americans with RMS. All the new clinical trials are under progress and anticipated to initiate recruitment in the coming months

Click here ­to­ read full press release/ article | Ref: Roche | Image: KRCU

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post